
    
      The study consisted of 3 parts. In Part 1 the loading dose was escalated while the
      maintenance dose was kept constant. In Part 2 the loading dose was kept constant while the
      maintenance dose was escalated. In Part 3 the recommended phase 2 loading and maintenance
      doses and schedule were administered to an expanded cohort to explore safety and efficacy of
      dalotuzumab.
    
  